- RecruitingPHASE3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study is looking at a new medicine called Satralizumab for children aged 2-11 with a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will primarily check how the medicine moves through the body, with a broad look at how well it works and if it's safe.
For: Neuromyelitis Optica Spectrum Disorder · NMOSDUnited States · Argentina · China - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
This study is testing a new medicine called satralizumab for people with Thyroid Eye Disease (TED). Researchers want to see if it's safe and effective, and how it works in the body to help improve the condition.
For: Thyroid Eye DiseaseUnited States · Canada · China - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
This study is looking at a new medicine called satralizumab for people with Thyroid Eye Disease (TED). We want to see if it works well, if it's safe, and how it affects the body.
For: Thyroid Eye Disease · TEDUnited States · Argentina · Australia - Not yet recruitingPHASE4
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
This study compares five medicines for Neuromyelitis Optica Spectrum Disorder (NMOSD) affecting the eyes and spinal cord. It aims to find which treatment best prevents relapses and has the fewest side effects for adults with NMOSD.
For: NMOSDUnited States · Germany